These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15981032)

  • 1. Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.
    Takada J; Iba K; Yamashita T
    J Bone Miner Metab; 2005; 23(4):333-6. PubMed ID: 15981032
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
    Siris E; Weinstein RS; Altman R; Conte JM; Favus M; Lombardi A; Lyles K; McIlwain H; Murphy WA; Reda C; Rude R; Seton M; Tiegs R; Thompson D; Tucci JR; Yates AJ; Zimering M
    J Clin Endocrinol Metab; 1996 Mar; 81(3):961-7. PubMed ID: 8772558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover in Paget's disease of bone.
    Delmas PD
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
    Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
    Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of biochemical markers of bone turnover in Paget's disease of bone].
    Vignot E; Meunier PJ
    Ann Biol Clin (Paris); 2001; 59(3):309-11. PubMed ID: 11397680
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-term intravenous therapy with Neridronate in Paget's disease.
    Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
    Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
    Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
    Bone; 1994; 15(3):261-7. PubMed ID: 8068446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
    Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
    Grasemann C; Schündeln MM; Hövel M; Schweiger B; Bergmann C; Herrmann R; Wieczorek D; Zabel B; Wieland R; Hauffa BP
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3121-6. PubMed ID: 23788687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
    Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
    Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate in the treatment of Paget's disease of bone.
    Khan SA; Vasikaran S; McCloskey EV; Benéton MN; Rogers S; Coulton L; Orgee J; Coombes G; Kanis JA
    Bone; 1997 Mar; 20(3):263-71. PubMed ID: 9071478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.